These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 37305209)

  • 1. An update on the discovery and development of reversible covalent inhibitors.
    Faridoon ; Ng R; Zhang G; Li JJ
    Med Chem Res; 2023; 32(6):1039-1062. PubMed ID: 37305209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expanding repertoire of covalent warheads for drug discovery.
    Mehta NV; Degani MS
    Drug Discov Today; 2023 Dec; 28(12):103799. PubMed ID: 37839776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophilic warheads in covalent drug discovery: an overview.
    Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
    Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Versatile Bioconjugation Chemistries of ortho-Boronyl Aryl Ketones and Aldehydes.
    Cambray S; Gao J
    Acc Chem Res; 2018 Sep; 51(9):2198-2206. PubMed ID: 30110146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced approaches of developing targeted covalent drugs.
    Gai C; Harnor SJ; Zhang S; Cano C; Zhuang C; Zhao Q
    RSC Med Chem; 2022 Dec; 13(12):1460-1475. PubMed ID: 36561076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitriles: an attractive approach to the development of covalent inhibitors.
    Bonatto V; Lameiro RF; Rocho FR; Lameira J; Leitão A; Montanari CA
    RSC Med Chem; 2023 Feb; 14(2):201-217. PubMed ID: 36846367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in covalent warheads for in vivo targeting of endogenous proteins.
    Shindo N; Ojida A
    Bioorg Med Chem; 2021 Oct; 47():116386. PubMed ID: 34509863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technologies for Direct Detection of Covalent Protein-Drug Adducts.
    Mons E; Kim RQ; Mulder MPC
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements.
    Yang J; Tabuchi Y; Katsuki R; Taki M
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Label-Free Bottom-Up Proteomic Workflow for Simultaneously Assessing the Target Specificity of Covalent Drug Candidates and Their Off-Target Reactivity to Selected Proteins.
    Yang Y; Shu YZ; Humphreys WG
    Chem Res Toxicol; 2016 Jan; 29(1):109-16. PubMed ID: 26675335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benchmarking in vitro covalent binding burden as a tool to assess potential toxicity caused by nonspecific covalent binding of covalent drugs.
    Dahal UP; Obach RS; Gilbert AM
    Chem Res Toxicol; 2013 Nov; 26(11):1739-45. PubMed ID: 24164572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible Covalent Inhibition─Desired Covalent Adduct Formation by Mass Action.
    Patel D; Huma ZE; Duncan D
    ACS Chem Biol; 2024 Apr; 19(4):824-838. PubMed ID: 38567529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
    Aljoundi A; Bjij I; El Rashedy A; Soliman MES
    Protein J; 2020 Apr; 39(2):97-105. PubMed ID: 32072438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of covalent prolyl oligopeptidase boronic ester inhibitors.
    Plescia J; Dufresne C; Janmamode N; Wahba AS; Mittermaier AK; Moitessier N
    Eur J Med Chem; 2020 Jan; 185():111783. PubMed ID: 31732257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the Compatibility between Warheads and Peptidomimetic Sequences of Protease Inhibitors-A Comprehensive Reactivity and Selectivity Study.
    Müller P; Meta M; Meidner JL; Schwickert M; Meyr J; Schwickert K; Kersten C; Zimmer C; Hammerschmidt SJ; Frey A; Lahu A; de la Hoz-Rodríguez S; Agost-Beltrán L; Rodríguez S; Diemer K; Neumann W; Gonzàlez FV; Engels B; Schirmeister T
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics.
    Cheke RS; Kharkar PS
    Drug Dev Res; 2024 Feb; 85(1):e22132. PubMed ID: 38054744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
    Gehringer M; Laufer SA
    J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
    Hillebrand L; Liang XJ; Serafim RAM; Gehringer M
    J Med Chem; 2024 May; 67(10):7668-7758. PubMed ID: 38711345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylfluorosulfate-Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal.
    Martín-Gago P; Olsen CA
    Angew Chem Int Ed Engl; 2019 Jan; 58(4):957-966. PubMed ID: 30024079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.